Other correlative studies from clinical trials of neoadjuvant immunotherapy in patients with resectable NSCLC did not show an association of PD-L1 expression in tumor cells with a clinical benefit of treatment [25,39,60,61,62]. Here, CD274 is linked to neoplasm.